{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:23:35Z","timestamp":1792315415582,"version":"4.4.0"},"reference-count":8,"publisher":"JLE","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Dermatol"],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1684\/ejd.2017.3192","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:12:59Z","timestamp":1696864379000},"page":"129-130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure"],"prefix":"10.1684","volume":"28","author":[{"given":"Kazumasa","family":"Oya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruriko","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Ishitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Okiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"3192_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"L. Khoja","year":"2015","unstructured":"Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM. Pembrolizumab. J Immunother Cancer 2015; 3: 36.","journal-title":"J Immunother Cancer"},{"key":"3192_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C. Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521\u201332.","journal-title":"N Engl J Med"},{"key":"3192_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/23120541.00081-2016","volume":"3","author":"V. Leroy","year":"2017","unstructured":"Leroy V, Templier C, Faivre JB, et al. Pembrolizumab-induced pneumonitis. ERJ Open Res 2017; 3: 1\u20134.","journal-title":"ERJ Open Res"},{"key":"3192_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4137\/DTI.S31565","volume":"10","author":"P. Fragkou","year":"2016","unstructured":"Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A. A case of organizing pneumonia (OP) associated with pembrolizumab. Drug Target Insights 2016; 10: 9\u201312.","journal-title":"Drug Target Insights"},{"key":"3192_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/annonc\/mdw178","volume":"27","author":"P.O. Fiset","year":"2016","unstructured":"Fiset PO, Shapera S, Butler MO, Tsao MS. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. Ann Oncol 2016; 27: 1649\u201350.","journal-title":"Ann Oncol"},{"key":"3192_CR6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M. Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 1607\u201316.","journal-title":"JAMA Oncol"},{"key":"3192_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J. Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23\u201334.","journal-title":"N Engl J Med"},{"key":"3192_CR8","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"J.S. Weber","year":"2016","unstructured":"Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943\u201355.","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2017.3192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1684\/ejd.2017.3192\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1684\/ejd.2017.3192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2017.3192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:18:00Z","timestamp":1741191480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ejd.2017.3192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1684\/ejd.2017.3192","relation":{},"ISSN":["1952-4013"],"issn-type":[{"value":"1952-4013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"assertion":[{"value":"3 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}